Apixaban versus Warfarin in Patients with Atrial Fibrillation

20118,832 citationsJournal Articlebronze Open Access

Authors

Christopher B. Granger · Duke University

John H. Alexander · Duke Medical Center

John J.V. McMurray

Renato D. Lópes · Clinical Research Institute

Elaine M. Hylek · University Medical Center

Michael G. Hanna · Bristol-Myers Squibb (United States)

Hussein R. Al‐Khalidi · Clinical Research Institute

Abstract

In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Antiplatelet Therapy and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 365, Issue 11, pp. 981-992

DOI: 10.1056/nejmoa1107039

Field-Weighted Citation Impact: 383.78